A New Blood Test Can Help Detect Colon Cancer, but It’s Not as Good as the Test You Hate to Take

Why It Matters

The ACS recommendation may increase screening uptake, potentially catching cancers earlier among reluctant patients and reducing overall mortality. It also signals a shift toward less invasive diagnostics in oncology care.

Key Takeaways

• Blood test detects colorectal cancer DNA markers in a simple draw
• ACS now endorses test for patients avoiding colonoscopy
• Sensitivity remains lower than colonoscopy, especially for early-stage tumors
• Could expand screening rates among underserved and reluctant populations

Pulse Analysis

Colorectal cancer remains the second leading cause of cancer death in the United States, largely because early disease is often asymptomatic. Traditional colonoscopy, while highly accurate, suffers from low patient compliance due to its invasiveness, preparation requirements, and perceived discomfort. In recent years, liquid biopsy technologies have matured, allowing clinicians to detect tumor‑derived DNA fragments circulating in the bloodstream. This blood test leverages methylation patterns specific to colorectal tumors, offering a non‑invasive, office‑based screening tool that can be performed alongside routine blood work.

The American Cancer Society’s endorsement marks the first time a major oncology organization has formally backed a blood‑based screen for colorectal cancer. Validation studies cited by the ACS indicate a sensitivity of roughly 70 % for detecting stage III and IV disease, but only about 45 % for stage I tumors, compared with colonoscopy’s near‑100 % detection across stages. Specificity exceeds 90 %, reducing false‑positive follow‑up procedures. The ACS recommendation targets individuals who decline colonoscopy or lack access to endoscopic services, positioning the test as a complementary pathway rather than a replacement.

From a market perspective, the approval could accelerate investment in liquid biopsy platforms, prompting insurers to consider coverage for the test as a preventive service. Healthcare systems may see reduced procedural costs and improved patient adherence, especially in underserved communities where colonoscopy resources are scarce. However, clinicians will need to balance the convenience of the blood test against its lower sensitivity, ensuring that positive results trigger timely colonoscopic confirmation. Ongoing trials aim to refine assay performance, potentially narrowing the gap with traditional screening and reshaping colorectal cancer prevention strategies.